Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD)
Phase 1
Completed
- Conditions
- Age-Related Macular Degeneration
- First Posted Date
- 2007-05-16
- Last Posted Date
- 2010-03-18
- Lead Sponsor
- Potentia Pharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT00473928
- Locations
- 🇺🇸
United States, Minnesota, Rochester, Minnesota, United States
🇺🇸United States, Florida, Miami, Florida, United States
🇺🇸United States, New Hampshire, Portsmouth, New Hampshire, United States
© Copyright 2025. All Rights Reserved by MedPath